Affiliation:
1. Federal State Budgetary Institution «N. N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N. N. Blokhin NMRCO); I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University)
2. Federal State Budgetary Institution «N. N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N. N. Blokhin NMRCO)
Abstract
Introduction. The search for new methods of therapy for non-small cell lung cancer (NSCLC) is an urgent task of modern science. Gefitinib is a targeted drug widely used in the treatment of NSCLC in patients with a mutation in the epidermal growth factor receptor tyrosine kinase domain. However, using of gefitinib and other drugs from the group of tyrosine kinase inhibitors is to limited by rapidly developing resistance, for this reason finding of a ways overcome drug resistance is actual part of research interests.Text. The review is devoted to the use of gefitinib in modern developments: introduction to various targeted delivery systems (liposomes, micelles, microspheres, etc.), studying it in combination with other chemotherapeutic agents, as well as in combination with photo- or thermosensitive compounds in various micro- and nanostructured complexes.Conclusion. As a result of the analysis of literature data, it was shown that, despite the fact that gefitinib is a first-generation drug, foreign and Russian researchers consider it quite promising for further use in the treatment of NSCLC. At the same time, developments are being carried out both in the field of expanding combination therapy and in the field of creating complex structures of targeted action, into which, in addition to gefitinib, photosensitizers or other compounds with photo- or thermosensitive effects are introduced.
Publisher
Center of Pharmaceutical Analytics Ltd
Reference32 articles.
1. Fedyayev D. V., Zyryanov S. K. Pharmacoeconomic Analysis of Afatinib and Gefitinib for the Treatment of Lung Cancer. Medical Technologies. Assessment and Choice. 2018;1(31): 68–84. (In Russ.)
2. Ryazhenov V. V., Gorokhova S. G. Clinico-economic evaluation of different treatment strategies in patients with non-small cell lung cancer and mutations in the EGFR gene. Journal of Modern Oncology. 2016;18(3):84–89. (In Russ.)
3. Sanarova E. V., Lantsova A. V., Nikolaeva L. L., Oborotova N. A., Litvinenko Ya. E., Solovyova N. L. Creation of a model of complex nanodelivery systems containing a tyrosine kinase inhibitor and a photosensitizer. Pharmaceutical Chemistry Journal. 2023;57(7):43–46. (In Russ.) DOI: 10.30906/0023-1134-2023-57-7-43-46.
4. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., Seto T., Satouchi M., Tada H., Hirashima T., Asami K., Katakami N., Takada M., Yoshioka H., Shibata K., Kudoh S., Shimizu E., Saito H., Toyooka S., Nakagawa K., Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology. 2010;11(2):121–1288. DOI: 10.1016/S1470-2045(09)70364-X.
5. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New England Journal of Medicine. 2010;24;362(25):2380–2388. DOI: 10.1056/NEJMoa0909530.